Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837557 | 0.88 | HDAC6 (0.70) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL12688087 | 0.82 | HDAC6 (0.67) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL12688086 | 0.81 | HDAC6 (0.68) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL15522589 | 0.81 | SMN1; SMN2 (0.64) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| Bufexamac SCHEMBL25215 | 0.80 | KDM4E (1.00) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| Bufexamac SCHEMBL5076113 | 0.80 | KDM4E (1.00) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL4579963 | 0.79 | HDAC6 (0.66) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL15522500 | 0.79 | HTT (0.65) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| Bufexamac SCHEMBL15456779 | 0.79 | KDM4E (0.97) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL15522678 | 0.78 | HDAC1 (0.74) | HDAC6KDM4ESMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | claimed |
| WO-2014041424-A1 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | METHYLGENE INC. (CA) | 2014-03-20 | — | — | WO | claimed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | HDAC1, HDAC5, HDAC7 | HDAC6 10/4885KDM4E 141/4885SMN1; SMN2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.